Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

Jianbiao Zhou, Chonglei Bi, Lip-Lee Cheong, Sylvia Mahara, Shaw-Cheng Liu, Kian-Ghee Tay, Tze-Loong Koh, Qiang Yu, Wee-Joo Chng

Blood (2011) 118 (10): 2830–2839.

https://doi.org/10.1182/blood-2010-07-294827

Published: 2011

Includes: Supplemental data

Journal Articles

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Jianbiao Zhou, M.D., Ph.D., Chonglei Bi, B.sc., Shaw-Cheng Liu, Kian-Ghee Tay, Lip-Lee Cheong, B.sc., Tze-Loong Koh, B.sc., Qiang Yu, Ph.D., Wee-Joo Chng, MRCP, MRCPath

Blood (2010) 116 (21): 4355.

https://doi.org/10.1182/blood.V116.21.4355.4355

Published: 2010

Journal Articles

Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition

Sai Mun Leong, Ban Xiong Tan, Baidah Bte Ahmad, Tie Yan, Lai Yuen Chee, Swee Tin Ang, Kian Ghee Tay, Liang Piu Koh, Allen Eng Juh Yeoh, Evelyn Siew-Chuan Koay, Yu-Keung Mok, Tit Meng Lim

Blood (2010) 116 (17): 3286–3296.

https://doi.org/10.1182/blood-2009-12-256149

Published: 2010

Includes: Supplemental data

Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen

Blood (2009) 113 (17): 4052–4062.

https://doi.org/10.1182/blood-2008-05-156422

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2008) 112 (11): 1618.

https://doi.org/10.1182/blood.V112.11.1618.1618

Published: 2008

NARROW

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Email alerts

ASH Publications

American Society of Hematology

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only